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Abstract
Two international multicentre randomised controlled trials of
drotrecogin alfa (activated) (DrotAA), the Recombinant Human
Activated Protein C Worldwide Evaluation of Severe Sepsis
(PROWESS) and Administration of Drotrecogin Alfa (Activated) in
Early Stage Severe Sepsis (ADDRESS) trials, have produced
inconsistent results. When 28-day mortality data from these trials for
patients with severe sepsis and at high risk of death are pooled using
a standard random-effects meta-analysis technique, there is no
statistically significant survival benefit (for patients with Acute
Physiology and Chronic Health Evaluation (APACHE II) scores of 25
or more), or a borderline significant benefit (for patients with multi-
organ failure). We argue that two important methodological issues
might explain the disparate results between the two trials. These
issues centre on early trial stopping, which exaggerates treatment
effects, and reliance on subgroup analyses, which for DrotAA yields
inconsistent results across different definitions of high risk. These
concerns call into question the effectiveness of DrotAA in any
patients with severe sepsis. Consequently, further randomised trials
of this agent in prospectively defined high-risk patients are required
to clarify its role in the management of severe sepsis.
Introduction
Severe sepsis is a condition with important public health
ramifications because it is common and has a high case-
fatality rate [1]. Drotrecogin alfa (activated) (DrotAA), more
commonly known as recombinant human activated protein
C, is the first specific therapy for sepsis to show an
important survival benefit. On the basis of the favourable
results of the Recombinant Human Activated Protein C
Worldwide Evaluation of Severe Sepsis (PROWESS) trial
[2], DrotAA was approved for patients with severe sepsis
and at high risk of death. However, regulatory approval for
DrotAA was controversial [3,4], and the recently published
Administration of Drotrecogin Alfa (Activated) in Early Stage
Severe Sepsis (ADDRESS) trial [5] has heightened this
controversy. The results of this study demonstrated no
evidence of benefit for DrotAA in patients with severe sepsis
and at low risk of death, and unexpectedly raised concerns
regarding its efficacy among patients at high risk of death
[6]. In this commentary we argue that the cumulative
evidence for a survival benefit in DrotAA-treated patients
with severe sepsis and at high risk of death is weaker than
originally believed. We also suggest methodological
explanations for discrepant results of these two rigorous
multicentre trials. These findings have important implications
not only for clinicians treating patients with severe sepsis but
also for the interpretation of other single, seemingly pivotal,
randomised controlled trials.
Effect of DrotAA on 28-day survival
Figure 1 shows the effect of DrotAA therapy on 28-day
survival, as observed in all three published trials (a phase II
trial [7], PROWESS [2], and ADDRESS [5]) and in an
additional unpublished trial in children with severe sepsis [8].
(A recent systematic review and health technology
assessment of DrotAA [9] found no additional trials.)
PROWESS suggested a survival benefit for all severely
septic patients who received DrotAA. This survival benefit
seemed to be concentrated in patients at high risk of death,
defined either by an Acute Physiology and Chronic Health
Evaluation (APACHE II) [10] threshold of 25 or by multiple
organ failure. Consequently, regulatory authorities restricted
DrotAA approval to severely septic patients with an APACHE II
score of 25 or more (USA) or multiple organ failure (many
European countries). The ADDRESS study provided new
data and an excellent opportunity to retest the hypothesis that
DrotAA is effective only in these high-risk subgroups. Although
designed to study patients at low risk of death, ADDRESS
enrolled patients with an APACHE II score of 25 or more, or
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multiple organ failure, when investigators perceived the risk of
death to be low on other clinical grounds.
Figure 2 shows, for PROWESS [2,11] and ADDRESS
[5,12], the effect of therapy on patients grouped by risk of
death. These subgroup data are not published for the phase II
adult trial or for the paediatric trial. We pooled results by
using standard meta-analysis software (Review Manager,
Version 4.2; The Cochrane Collaboration, Oxford, UK) and a
conservative random-effects model. Pooled estimates confirm
no evidence of benefit for DrotAA in low-risk patients. For
high-APACHE II patients, the results vary substantially
between studies (p = 0.01 for heterogeneity, I2 = 84%;
I2 describes the percentage of total variation in results across
studies that is due to heterogeneity rather than chance [13]),
and pooled data show a trend towards survival benefit that is
not statistically significant. For high-risk patients defined by
multiple organ failure, the two trials are more consistent
(p = 0.23 for heterogeneity, I2 = 32%), with the pooled results
suggesting a clinically important survival benefit that just
reaches the conventional threshold for statistical significance.
To summarize, these analyses show that the effect of DrotAA
varies substantially between the two adult trials overall, and in
the high-risk subgroups. This suggests that the PROWESS
trial’s estimate of survival benefit in severely septic patients
might not be robust and that the true effect is probably more
modest.
Explanations for disparate results in high-risk
patients
DrotAA investigators have postulated several explanations for
this between-trial difference in treatment effect among high-risk
patients. These include a lower average APACHE II score and
baseline risk of death in the high-APACHE II subgroup of
ADDRESS than in PROWESS [5] and potential misclassifica-
tion of patients with respect to the APACHE II threshold of 25
in ADDRESS [14]. The first observation suggests that the
treatment effect of DrotAA may be quite variable even in
patients with an APACHE II score of 25 or more, and the
second highlights the practical difficulty of applying any
APACHE II threshold to patient selection for DrotAA.
Investigators also discovered a higher prevalence of poor
prognostic factors in patients receiving DrotAA, compared with
placebo, in the high-APACHE II subgroup of ADDRESS [12].
An adjusted analysis incorporating relevant baseline covariates
would address this possibility. Similar adjusted analyses should
be performed for the PROWESS trial, because at least some
poor prognostic factors seem to be more prevalent in the high-
risk placebo subgroups [15]. However, even if the adjusted
and unadjusted analyses were to differ, more data would still
be required to clarify the discrepant findings.
Two other more general methodological considerations may
be more important in explaining the differences between the
PROWESS and ADDRESS results.
First, in stopping early after a predefined interim analysis, the
PROWESS trial probably overestimated the treatment effect
[16,17]. Current research suggests that such overestimation
is less prominent in trials accumulating a large number of
outcome events [16], such as PROWESS (469 outcome
events and p = 0.005 for overall survival benefit). However,
another recent sepsis trial illustrates the potential hazard of
stopping early even after accumulating many outcome events.
In the randomised placebo-controlled Optimized Phase 3
Tifacogin in Multicenter International Sepsis Trial (OPTIMIST)
[18], investigators studied the effect of tifacogin (recombinant
tissue factor pathway inhibitor) in patients with severe sepsis
and an elevated international normalized ratio. A planned
interim analysis of the first 722 patients (about 245 events)
demonstrated a significant mortality improvement in patients
receiving  tifacogin (29.1% versus 38.9%, p = 0.006). How-
ever, after reaching the target enrolment of 1,754 patients (597
events), the apparent mortality difference disappeared
(34.2% versus 33.9%, p = 0.88). Similar issues have arisen
in oncology trials [19,20]. These examples illustrate the
potentially misleading estimates of treatment effect when
trials are stopped early for efficacy, even if supported by
many events and extreme p values.
Figure 1
Relative risk (RR) and 95% confidence intervals (95% CI) for 28-day mortality in each study. RR is plotted on the natural logarithm scale. n/N =
number of deaths at 28 days divided by the total number of patients randomly assigned to drotrecogin alfa (activated) or placebo. For the phase II
trial, only patients who were randomized to the same dose and duration of drotrecogin alfa (activated) used in the Recombinant Human Activated
Protein C Worldwide Evaluation of Severe Sepsis (PROWESS) and Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis
(ADDRESS) trials are included [37].Page 3 of 5
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Second, the PROWESS and ADDRESS trials differed in the
results of an analysis of the effect of DrotAA in high-APACHE
II versus low-APACHE II patients: PROWESS found a
differential effect, whereas ADDRESS did not. This raises the
possibility that this subgroup effect in PROWESS was due to
chance. Current teaching [21–23] suggests that results of
subgroup analyses are most likely to be true when they are
pre-specified, and when large in magnitude and statistically
significant – all of which were true of the PROWESS
APACHE II subgroup analysis. However, it was one of about
25 pre-specified subgroup analyses (rather than one of few),
it was not consistent across different definitions of high risk
(such as presence versus absence of multiple organ failure,
mechanical ventilation, or vasopressor support) [11], there is
no other independent evidence to support this subgroup
effect, and the biological rationale for it is unclear. If the high-
APACHE II versus low-APACHE II subgroup effect in
PROWESS is due to chance, then the best estimate of
DrotAA’s effect for any patient is the overall pooled result of
the two trials, which demonstrates no statistically significant
benefit (relative risk 0.93, 95% confidence interval 0.69 to
1.26). [The pooled estimate is very similar whether the phase II
patients are also included (relative risk 0.95, 95% confidence
interval 0.72 to 1.25) or all four trials shown in Figure 1 are
included (relative risk 0.94, 95% confidence interval 0.76 to
1.17)]. Alternatively, if this subgroup effect is real, the pooled
analyses in Figure 2 show that the degree of survival benefit
depends on the operational definition of ‘high risk of death’
and at best just reaches the conventional threshold for
statistical significance. In either case, more data are required
to clarify the degree of benefit, if any, in this or any other
subgroup of patients with severe sepsis.
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Figure 2
Effect of drotrecogin alfa (activated) on 28-day mortality. Results are classified by low-risk and high-risk subgroups from the Recombinant Human
Activated Protein C Worldwide Evaluation of Severe Sepsis (PROWESS) and Administration of Drotrecogin Alfa (Activated) in Early Stage Severe
Sepsis (ADDRESS) trials, defined by either Acute Physiology and Chronic Health Evaluation (APACHE II) score (less than 25, and 25 or more) or
organ failure (single and multiple). Weight refers to the contribution of each study to the overall pooled estimate of treatment effect for each low-
risk and high-risk subgroup. The weight of each study is calculated as the inverse of the variance of the natural logarithm of its relative risk. Each
summary relative risk (RR) is plotted on the natural logarithm scale. The size of the symbol denoting each point estimate approximates the
weighting of each study to each pooled effect measure. Each pooled effect measure is calculated with the use of a random-effects model. n/N =
number of deaths at 28 days divided by the total number of patients in each particular subgroup randomly assigned to drotrecogin alfa (activated)
or placebo. The numbers of patients and deaths at 28 days in each subgroup were estimated from data provided in references [2], [4] and [11] for
the PROWESS trial, and in references [5] and [12] for the ADDRESS trial.Comparisons with other sepsis therapies
Single randomised controlled trials of two other therapies
have recently suggested mortality benefits in critically ill
patients. A trial of intensive insulin therapy was stopped early
for benefit [24], and another trial showed that low-dose
steroid treatment improved survival in a pre-specified
subgroup of patients with vasopressor-dependent septic
shock [25]. Both treatments have been incorporated into
current consensus recommendations for the treatment of
severe sepsis [26], similarly to the situation for DrotAA. To
confirm the encouraging results of both studies, further trials
are being conducted [27-31]. This situation contrasts with
DrotAA, for which, to our knowledge, no additional trials in
patients with sepsis and at high risk of death are either under
way or planned to confirm initial findings and to resolve the
subgroup discrepancies.
Conclusion
Patients with severe sepsis and at high risk of death are
among the most vulnerable patients in the intensive care unit.
In the light of new findings from the ADDRESS trial, the role
for DrotAA in these patients is less clear than before. Others
have raised important safety concerns by observing a higher
risk of serious bleeding, including intracranial haemorrhage, in
open-label use [32,33]. We share the concerns of others
[3,15,33-36] and believe that further trials of DrotAA in
prospectively defined high-risk patients are required to clarify
its role in the management of severe sepsis.
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